Thermo Fisher Scientific Inc. $TMO Shares Bought by Canada Post Corp Registered Pension Plan

Key Points

• Canada Post’s pension plan increased its Thermo Fisher stake by 11.7% in the second quarter, reaching 45,314 shares valued at approximately $22.7 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with adjusted EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $619.41. Insiders, however, sold 52,053 shares worth about $30.6 million over the past 90 days.

Canada Post Corp Registered Pension Plan lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,314 shares of the medical research company's stock after purchasing an additional 4,734 shares during the quarter. Thermo Fisher Scientific comprises 0.8% of Canada Post Corp Registered Pension Plan's portfolio, making the stock its 29th largest position. Canada Post Corp Registered Pension Plan's holdings in Thermo Fisher Scientific were worth $22,719,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. State Street Corp boosted its position in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after acquiring an additional 229,630 shares during the period. Capital World Investors grew its position in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock valued at $4,728,129,000 after buying an additional 26,425 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lisa P. Britt sold 5,850 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at $8,574,720. This represents a 28.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last ninety days. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price on the stock. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and cut their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Piper Sandler raised their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a report on Monday, July 27th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Finally, Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Stock Down 1.3%

Shares of NYSE:TMO opened at $588.17 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business has a fifty day simple moving average of $529.37 and a 200 day simple moving average of $509.58. The firm has a market cap of $217.48 billion, a P/E ratio of 31.64, a P/E/G ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter last year, the firm posted $4.28 earnings per share. The firm's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source